Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

A Promise Made at Six: The Winding Road to Cancer Research

An Interview with Priyanka Joshi, Associate Scientist in Analytical Development Introduction Cancer remains one of the world's greatest healthcare challenges, driving scientists to develop more effective and precise treatment approaches. Among the most promising innovations are cell therapies, which harness the body's own immune system to fight cancer. Behind these advances are scientists working to…
August 5, 2026

Read more

EVENTS

Global Pharma Partnering Summit 2026 | Nov 2–3, 2026 | Hyderabad, India

The pharmaceutical industry is entering a new era where innovation is no longer driven by individual organisations alone. From drug discovery and clinical research to manufacturing, regulatory compliance, digital transformation, and global commercialisation, success increasingly depends on strategic partnerships that combine expertise, technology, and shared ambition. The Global Pharma Partnering Summit 2026 serves as a…
July 31, 2026

Read more

EVENTS

AI, Forecasting, Insights and Analytics for Smarter Decisions in Pharma 2026 | Nov 16–17 | London, UK

Advance forecasting, AI and analytics to drive strategic commercial decision-making across functions in Pharma The Marcus Evans AI, Forecasting, Insights and Analytics for Smarter Decisions in Pharma conference will explore how pharma leaders are embedding Gen AI for long-term forecasting, Agentic AI for Real-World-Evidence generation and advanced analytics into cross-functional workflows to improve forecasting confidence, commercial responsiveness and long-term strategic planning…
July 31, 2026

Read more

EXCLUSIVE

Gona Aziz at HLTH Europe 2026 on the Convergence of AI & 5T MRI: United Imaging’s Strategy for Advancing Precision Healthcare 

Shots  United Imaging is advancing the future of radiology through the convergence of ultra-high-field imaging and AI, with the uMR Jupiter 5T enabling unprecedented anatomical and functional visualization while next-generation AI transforms imaging data into actionable clinical insights that support earlier diagnosis, precision medicine, and personalized patient care.  At HLTH Europe 2026, the company highlighted how 5T whole-body MRI expands clinical…
July 20, 2026

Read more

VIEWPOINTS

Michael Wysocki on Precision Molecular Imaging & PSMA PET Innovation: Blue Earth Diagnostics’ Vision for Personalized Prostate Cancer Care

Shots:  Blue Earth Diagnostics is advancing precision molecular imaging in prostate cancer through its F-18 PET imaging portfolio, with POSLUMA and Axumin designed to improve disease localization, support earlier clinical decision-making, and enhance physician confidence, particularly in patients experiencing biochemical recurrence.  At SNMMI 2026, the company presented new evidence highlighting POSLUMA's strong detection performance at low PSA levels, reduced urinary…
July 13, 2026

Read more

VIEWPOINTS

Redefining Asthma Care: Caterina Brindicci and James Teague on Breztri Aerosphere’s US Approval and the Future of Triple Therapy  

Shots  Breztri Aerosphere became the first and only fixed-dose triple-combination maintenance therapy approved in the US for asthma patients aged 12 years and older, expanding beyond COPD and reinforcing the role of single-inhaler triple therapy in advancing asthma care.  The approval strengthens AstraZeneca’s respiratory portfolio and long-term vision of transforming care beyond symptom control, with additional regulatory reviews…
July 6, 2026

Read more

VIEWPOINTS

Expanding COPD Treatment Horizons: Caterina Brindicci and Frank Sciurba on Tozorakimab’s Phase III Journey  

Shots:  Tozorakimab reinforced its potential as a first-in-class COPD biologic with a third positive Phase III trial (MIRANDA), complementing OBERON and TITANIA and strengthening AstraZeneca’s regulatory package while validating IL-33 as a critical therapeutic pathway in COPD.  The MIRANDA trial demonstrated efficacy across one of the broadest COPD populations studied for a biologic, including former and current smokers, patients across…
June 29, 2026

Read more

VIEWPOINTS

Judith Greciet on Targeting Iron Dysregulation: PulseSight’s Next-Generation Approach to Geographic Atrophy  

Shots:  PulseSight Therapeutics is advancing a novel approach to Geographic Atrophy (GA) with PST-611, a first-in-class non-viral gene therapy designed to restore iron homeostasis by targeting transferrin biology—an upstream driver of retinal degeneration.  At ARVO 2026, PST-611 delivered encouraging Phase I results, demonstrating an excellent safety and tolerability profile, stable visual acuity, and early signals of potential functional…
June 22, 2026

Read more

VIEWPOINTS

IL-33 Breakthrough in COPD: Caterina Brindicci and Frank Sciurba on Tozorakimab’s Phase III Success 

Shots:  Tozorakimab demonstrated a potential first-in-class advantage in COPD, becoming the first IL-33 biologic to achieve positive outcomes across three pivotal Phase III trials (OBERON, TITANIA, and MIRANDA), highlighting the clinical relevance of targeting both reduced and oxidized forms of IL-33 to reduce exacerbations in a broad patient population.  The LUNA Phase III programme enrolled the most comprehensive…
June 15, 2026

Read more

Load more